Effects of Pentoxifylline on the Haematologic Status in Anaemic Patients with Advanced Renal Failure

REFERENCES

• McGonigle RJS, Wallin JD, Shadduck RK, Fisher JVi/. Erythropoietin deficiency and inhibition or erythropoi-esis in renal insufficiency. Kidney Int 1984; 25: 437–44.
   Google Scholar
• McGonigle RJS, Boineau FG, Beckman B, Ohene-Frempong K, Lewy JE, Shadduck RN, et al. Erythro-poietin and inhibitors of in vitro erythropoiesis in the development of anaemia in children with renal disease. J Lab Clin Med 1985; 105: 449–58.
   Google Scholar
• Derienzo DP, Saleem A. Anaemia of chronic disease: a review of pathogenesis. Tex Med 1990; 86: 80–3.
   PubMedGoogle Scholar
• Moldawer LL, Marano MA, Wei H, Fong Y, Siles ML, Kuo G, et al. Cachectin/tumour necrosis factor alpha alters red blood cell kinetics and induces anaemia in vivo. FASEB J 1989; 3: 1637–43.
   PubMed Web of Science ®Google Scholar
• Roodman GD, Johnson RA, Cibon U. Tumour necrosis factor alpha and anaemia of chronic renal disease, effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol 1989; 271: 185–96.
   Google Scholar
• Ogawa M. Effects of hemopoietic growth factors on stem cells in vitro. Hematol Oncol Clin North Am 1989; 8: 453–64.
   Google Scholar
• Means Jr RT. Pathogenesis of the anaemia of chronic disease: a cytokine-mediated anaemia. Stem Cells Dayt 1995; 13: 32–7.
   PubMed Web of Science ®Google Scholar
• Rogiers P. Zhang H, Leeman M, Nagler J, Neels H, Mélot C, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159–62.
   PubMed Web of Science ®Google Scholar
• Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50–97.
   PubMed Web of Science ®Google Scholar
• Thiel M, Bardenheuer H, Pöch G, Madel C, Peter K. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem Bio-phys Res Commun 1991; 180: 53–8.
   Google Scholar
• McDonald R. Pentoxifylline reduces injury to isolated lungs perfused with human neutrophils. Am Rev Respir Dis 1991; 144: 1347–50.
   PubMedGoogle Scholar
• Oismuller C, Mayer N, Micksche M, Steltzer H, Hammerle AF. In vivo modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Shock 1995; 4: 161–5.
   Google Scholar
• Cuvrie MS, Rao KM, Padmanabhan J, Jones A, Crawford J, Cohen HJ. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranula-tion, and superoxide production. J Leuk Biol 1990; 47: 244–50.
   PubMed Web of Science ®Google Scholar
• Williams Jr JH, Heshmat S, Tamadon J, Guerra J. Inhibition of alveolar macrophages by pentoxifylline. Crit Care Med 1991; 19: 1073–8.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, et al. Cellular and molecular regulation of tumour necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230–6.
   PubMed Web of Science ®Google Scholar
• Zabel P. Schonharting MM, Wolter DT, Schade UF. Opentifylline in endotoxaemia. Lancet 1989; 2: 1474–7.
   PubMed Web of Science ®Google Scholar
• Waage A, Sorensen M, Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 1990; 335: 543.
   Google Scholar
• Alegre ML, Gastaldello K, Abramowicz D, Kinnaert P. Vereerstraeten P. De Pawn L, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674–9.
   Google Scholar
• Dezube BJ, Fridovich-Keil JL, Bourard I, Lauge RF, Pardee AB. Pentoxifylline and well-being in patients with cancer. Lancet 1990; 335: 662.
   PubMed Web of Science ®Google Scholar
• Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/ tumour necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 1990; 172: 391–4.
   Google Scholar
• Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumour necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36: 57–60.
   Google Scholar
• Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, et al. Pentoxifylline decreases tumour necrosis factor expression and serum triglycer-ides in people with AIDS. J Acquir Immun Defic Syndrome 1993; 6: 787–94.
   PubMed Web of Science ®Google Scholar
• Manrique RV. Placebo-controlled double-blind study of pentoxifylline in sickle cell disease patients. J Med 1987; 18: 277–91.
   PubMedGoogle Scholar
• Mass RD, Venook AP, Linker CA, Zipkin RE. Pentoxifylline and aplastic anaemia. Ann Intern Med 1987; 107: 427–8.
   PubMed Web of Science ®Google Scholar
• Cassidy MID, Jager CD, Ebrahim O, Camachio P, Robson S. Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro. Nephrol Dial Transplant 1994; 9: 775–9.
   Google Scholar
• Eschbach JVV, Adamson JW. Hematologic consequences of renal failure. In: Brenner BM, Rector FC, editors. The kidney, 4th ed. Philadelphia: W. B. Saunders Co., 1991: 2019–35.
   Google Scholar
• Stevens JM, Kurtz A, Eckardt K, Winearls CG. Anaemia in chronic renal failure. In: Cameron S, Davison AM, Gffinfeld JP, Kerr D, Ritz E, editors. Oxford textbook of clinical nephrology. Oxford: Oxford University Press; 1992: 1344–60.
   Google Scholar
• Remuzzi G, Rossi EC. Hematologic consequences of renal failure. In: Brenner BM, editor. The Kidney. 5th ed. Philadelphia: W. B. Saunders, 1996: 2170–86.
   Google Scholar
• Herbelin A, Nguyen AT, Zingraff J, Urena P. Deschamps-Latscha B. Influence of uremia and hemo-dialysis on circulating interleukin-1 and tumour necrosis factor alpha. Kidney Int 1990; 37: 116–25.
   Google Scholar
• Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1fl, TNF (and
   Google Scholar
• Akahane K, Hosoi T, Urabe A, Kawakama M, Takaku
   Google Scholar
• Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumour necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–92.
   PubMed Web of Science ®Google Scholar
• Cibon U, Bonewald L, Caro J, Roodman GD. Erythro-poietin fails to reverse the anaemia in mice continuously exposed to tumour necrosis factor-alpha in vivo. Exp Hematol 1990; 18: 438–41.
   PubMed Web of Science ®Google Scholar
• Johnson RA, Wakkelow TA, Caro J, Olitt A, Roodman GD. Chronic exposure to tumour necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130–8.
   Google Scholar
• Danielson B. R-HuEPO hyporesponsiveness—who and why? Nephrol Dial Transplant 1995; 10 Suppl 2: 69–75.
   Google Scholar
• Johnson RA, Cook CA, Furmanski P. In vivo suppres-sion of erythropoiesis by tumour necrosis factor-a (TNF-a): reversal with exogenous erythropoietin. Exp Hematol 1990; 18: 109–15.
   Google Scholar